IRulya Therapeutics posts updated October 2026 corporate presentation on its website
IRulya Therapeutics posted an updated corporate presentation dated October 2026 on its investor website and furnished it as Exhibit 99.1 to this Form 8-K. The filing contains no financial results, guidance, or new financial statements; it describes the company's LAM-001 inhaled rapamycin programs and their expected timelines.
Key points
- The presentation was posted October 19, 2026, and filed under Regulation FD, so it is not deemed filed under Section 18 of the Exchange Act.
- The company lists LAM-001 Phase 2 data readouts: bronchiolitis obliterans syndrome (BOS) expected 1Q 2027, and PH-ILD Phase 2b expected 1Q 2028.
- The presentation states the SAPH Phase 2 trial is expected to start in 4Q 2026, and that the Phase 2a PH-ILD 24-week results were presented at ATS in May 2026 with a 6MWD mean change of +81.3 meters in six evaluable patients.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.